Pharmaceuticals company Strides Pharma Science announced Q2FY25 results Revenues at Rs 12,011 million, grew 17.0% YoY, compared to Rs 10,264 million during Q2FY24. Gross margin at Rs 7,032 million, grew 15.6% YoY. EBITDA grew 31% YoY to Rs 2,358 million with EBITDA margin at 19.6%, grew 209bps YoY. US revenues at a historic high of USD 75 million in Q2FY25, grew 26.2% YoY. Q2FY25 Adjusted PAT at Rs 1,103 million and Reported PAT at Rs 937 million. Reported EPS at Rs 10.1 and Adj EPS at Rs 12.0 for Q2FY25. Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, said: “We continue to deliver on the momentum built over several preceding quarters and delivered another strong quarter. Q2FY25 demonstrated sustained growth across all markets fueled by new product launches. US operations reported highest ever quarterly revenue of $75m in Q2FY25. Strong YoY improvement in absolute EBITDA and EBITDA margin reflects our continued focus on operational efficiency and profitability. Significant highlights of the quarter were: Release of our maiden Sustainability Report, underscoring our long-term commitment to Sustainability, ESG and responsible business practices. USD 95 million fundraising commitment from marquee investors for OneSource at an 82% premium to earlier valuation, unlocking ~Rs 61,000 million (~USD 725 million) value for Strides’ shareholders.” Result PDF